Last edition
News about "PARP1 inhibitor"
Duke Street Bio Gets EMA Approval to Launch PARP1-Selective Inhibitor Trial
This potentially best-in-class, potent, highly selective and CNS-penetrant agent targets cancers that harbour homologous recombination deficiencies (HRD) including BRCA mutations.
PARP1 Inhibitor | 25/09/2024 | By Aishwarya | 306
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members